ガイドラインを提示する脂質低下臨床試験の適用性 動脈硬化性心血管疾患の現代の現実の患者
Pauline C E Schuitema1, Manon C Stam-Slob1, Frank L J Visseren1
1Department of Vascular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
European heart journal. Quality of care & clinical outcomes
|August 29, 2025
まとめ
動脈硬化性心血管疾患 (ASCVD) を患っている実際の患者は 脂肪を減らすための古い試験の基準を満たしていないことが多いのです 異なる特徴にもかかわらず,適格な患者と不適格な患者のアウトカムは類似しており,試験の汎用性を検証した.
科学分野:
- 心血管医学
- 臨床試験
- 公衆衛生
背景:
- 脂質低下試験は,動脈硬化性心血管疾患 (ASCVD) の二次予防に役立つ.
- 厳格な適格性を持つ古い試験は,今日の多様なASCVD集団を代表しないかもしれません.
- この研究は,肝臓脂質低下試験における患者の実用性を評価するものです.
研究 の 目的:
- 臨床的特徴と臨床試験対象の患者と,試験対象の患者でない患者の長期的なアウトカムを比較する
- 過去の脂質低下ランダム化臨床試験 (RCT) の代表性を評価する.
主な方法:
- UCC- SMART研究 (2000 - 2023年) で,8つの脂質低下RCTから8,537人の現実世界ASCVD患者 (CAD,CeVD,PAD) に適格性の基準を適用した.
- 試験の適格性の割合と比較された臨床的特徴
- 競合するリスク分析を用いた循環性心血管疾患のリスクと全因死亡率の評価
主要な成果:
- 試験の適格性は幅広く変化した (CADでは9%,85%,CeVDでは7%,PADでは8%,72%),通常は以前の試験では高かった.
- 試験対象と非対象の患者は,ほとんどの試験において異なる臨床的特徴を示した.
- 異なるにもかかわらず,再発性心血管疾患のリスクと全原因死亡率は,グループ間ではほぼ同等であった.
結論:
- 実際のASCVD患者のリピッド低下RCTの適格性は,試験および疾患サブタイプによって大きく異なります.
- 適格な患者と不適格な患者の比較結果から,ガイドラインを参考にした試験は,現代のASCVD集団を広く代表していることが示唆される.
関連する概念動画
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
38
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
01:30Atherosclerosis I: Introduction
76
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
76
01:26Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32